Investigational Drug Information for Cilofexor
✉ Email this page to a colleague
What is the development status for investigational drug Cilofexor?
Cilofexor is an investigational drug.
There have been 10 clinical trials for Cilofexor.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 27th 2019.
The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Cholangitis. The leading clinical trial sponsors are Gilead Sciences, Novo Nordisk A/S, and [disabled in preview].
There are eight US patents protecting this investigational drug and one hundred and twenty-seven international patents.
Summary for Cilofexor
| US Patents | 8 |
| International Patents | 127 |
| US Patent Applications | 43 |
| WIPO Patent Applications | 15 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2019-03-27) |
| Vendors | 37 |
Recent Clinical Trials for Cilofexor
| Title | Sponsor | Phase |
|---|---|---|
| Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) | Novo Nordisk A/S | Phase 2 |
| Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) | Gilead Sciences | Phase 2 |
| Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis | Gilead Sciences | Phase 1 |
Clinical Trial Summary for Cilofexor
Top disease conditions for Cilofexor
Top clinical trial sponsors for Cilofexor
US Patents for Cilofexor
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Cilofexor | ⤷ Subscribe | FXR agonists and methods for making and using | Salk Institute for Biological Studies (La Jolla, CA) | ⤷ Subscribe |
| Cilofexor | ⤷ Subscribe | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (Foster City, CA) | ⤷ Subscribe |
| Cilofexor | ⤷ Subscribe | FXR (NR1H4) modulating compounds | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Subscribe |
| Cilofexor | ⤷ Subscribe | Acyclic antivirals | Janssen BioPharma, Inc. (South San Francisco, CA) | ⤷ Subscribe |
| Cilofexor | ⤷ Subscribe | FXR (NR1H4) binding and activity modulating compounds | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Subscribe |
| Cilofexor | ⤷ Subscribe | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (Foster City, CA) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Cilofexor
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Cilofexor | Australia | AU2015229072 | 2034-03-13 | ⤷ Subscribe |
| Cilofexor | Canada | CA2942403 | 2034-03-13 | ⤷ Subscribe |
| Cilofexor | European Patent Office | EP3116878 | 2034-03-13 | ⤷ Subscribe |
| Cilofexor | Japan | JP2017510572 | 2034-03-13 | ⤷ Subscribe |
| Cilofexor | South Korea | KR20160132111 | 2034-03-13 | ⤷ Subscribe |
| Cilofexor | World Intellectual Property Organization (WIPO) | WO2015138986 | 2034-03-13 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
